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Male gender
BMI > 30 kg/m2
LDL cholesterol without treatment >250 mg/dL
Hypertension
Diabetes
<5 years of lipid-lowering treatment
Onset of lipid-lowering at age >30 years
Positive genetic test for FH
Prevalence of a first cardiovascular disease event among HeFH after 9.7 years in high-intensity lipid-
lowering treatment stratified by the count of cardiovascular risk factors
Risk factors
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Abstract 
Background and aims: The impact on heterozygous familial hypercholesterolemia 
(HeFH) health led by high-intensity lipid-lowering therapy (HILLT) is unknown, and 
the question remains if there is still an unacceptably high residual risk to justify 
treatment with new lipid-lowering drugs.  
Methods: This observational, retrospective, multicenter, national study in Spain, whose 
information was obtained from a national dyslipemia registry was designed to establish 
the current prevalence of cardiovascular disease (CVD) in HeFH and to define the 
impact of HILLT on CVD in this population. Odds were estimated using several logistic 
regression models with progressive adjustment. 
Results: 1958 HeFH, mean age 49.3±14.3 years, were included in the analysis. At 
inclusion in the registry, 295 patients (15.1%) had suffered CVD and 164 (55.6%) had 
suffered the first event before the onset lipid-lowering treatment. Exposition to 
treatment associated more than ten times lower odds for CVD than those subjects naïve 
to treatment (OR 0.085, 95% CI 0.063-0.114, p<0.001). A first CVD event after a mean 
treatment period of 9.1±7.2 years occurred in 131 out of 1615 (8.1%) HeFH subjects 
and 115 (87.8%) of them were on HILLT. 
Conclusions: Current prevalence of CVD among HeFH is one third of that reported 
before the statins era. Early initiation and prolonged lipid-lowering treatment was 
associated with this reduction in CVD. New cases of CVD, in spite of HILLT appeared, 
mostly, among patients accumulating risk factors and probably they may be considered 
for further lipid-lowering drugs. 
 
Keywords 
Familial hypercholesterolemia, cardiovascular disease, lipid-lowering, statins 
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1. Introduction 
Familial hypercholesterolemia (FH) is one of the most common genetic diseases in 
the world [1]. The estimated prevalence of heterozygotes FH (HeFH) is one in every 
200-250 persons [2,3] and it is even higher in areas with some genetic isolation [4]. FH 
subjects are characterized by very high plasma concentration of low-density lipoprotein 
(LDL) cholesterol with autosomal co-dominant pattern of transmission, tendon 
xanthomas and high risk of premature coronary heart disease (CHD) [5]. Most cases of 
FH are caused by loss-of-function mutations in the genes encoding the LDL particle 
receptor (LDLR) [6], or apolipoprotein B (APOB) [7], but also by gain-of-function 
mutations in the genes encoding for proprotein convertase subtilisin/kexin type 9 
(PCSK9) [8] or apolipoprotein E (APOE) [9]. 
Untreated affected subjects have a markedly elevated long-term CHD risk, with 
hazard ratios up to 5.0 with respect to the general population [10], and early mortality 
with up to 100-fold increase from CHD in young adults. This high CHD risk reduces 
life expectancy in 20 years for men and 12 years for women [10]. Consequently, 
international clinical guidelines classified HeFH as a high-risk condition which deserves 
early diagnosis and treatment [1,5,12]. 
The advent of potent lipid-lowering drugs, specially 3-hydroxy-3-methyl-glutaryl-
CoA reductase inhibitors or statins, has been a landmark for people suffering from FH. 
Since the late 1980s this pharmacological therapy, sometimes in association with 
ezetimibe, has substantially reduced or even normalized LDL cholesterol concentrations 
in HeFH, and the natural history of the disease has been importantly modified [5]. 
Different reports from United Kingdom [13], Norway [14], Denmark [15] and The 
Netherlands [16] indicate that, although cardiovascular disease (CVD) remains 
significantly higher in treated heterozygous FH than in subjects from the general 
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population, CVD has substantially improved in HeFH in recent years. However, the 
impact on HeFH health led by high-intensity lipid lowering therapy is basically 
unknown, as well as the question whether it is sufficient with this treatment or still the 
residual risk is unacceptably high to justify treatment with new lipid-lowering drugs, 
such as PCSK9 inhibitors. 
Most diagnosed cases of HeFH in Spain, especially those with genetic diagnosis, are 
controlled in specialized lipid units distributed throughout the country that are organized 
in a network within the Spanish Atherosclerosis Society (SEA). SEA created in 2013 a 
National Registry that includes primary dyslipidemias using homogeneous clinical 
diagnostic criteria [17,18]. We hypothesized that lipid-lowering therapy has improved 
HeFH cardiovascular prognosis in recent years. Thus, the objective of this analysis was 
to establish the current prevalence of CVD in HeFH adults, and to assess the impact of 
high intensity lipid lowering treatment on CVD in this population. 
 
2. Material and methods 
2.1 Study characteristics 
This observational, retrospective, multicenter, national study in Spain was designed 
to determine current prevalence of CVD in patients with HeFH in the era of statin 
treatment. The impact of lipid lowering treatment was studied with a case-control 
approach. The information was obtained from the Dyslipidemia Registry of the SEA. 
This is an active online registry, where 50 certified lipid clinics distributed throughout 
all regions of Spain report cases of various types of primary hyperlipidemias [17]. The 
anonymous clinical data collection in this registry was approved by a central ethical 
committee (Comité Ético de Investigación Clínica de Aragón, CEICA). Inclusion 
criteria were standardized in 5 training sessions before case recruitment before. For 
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HeFH, the registry includes personal and family health history, anthropometry, physical 
examination, laboratory data, presence of CVD, age at which CVD events occurred, age 
at which statin treatment began, history of lipid-lowering treatment, and genetic data 
regarding mutations in LDLR, APOB or PCSK9 (positive, negative or unknown). 
Patients were eligible for inclusion in this study if they were 18 years of age or older 
with clinical or genetic diagnosis of HeFH. Clinical diagnosis was based on the 
diagnostic criteria proposed by the Dutch Lipid Clinics Network (DLCN): 6-8 points 
(probable), and >8 points (definite) [1]. Genetic diagnosis was based on tested carrier 
status of a known pathogenic mutation for FH.  Pathogenicity definition of mutations 
followed the American College of Medical Genetics ACMG recommendations [18]. 
Only pathogenic and likely pathogenic mutations were considered as causal in this 
analysis. Additional written informed consent was required for genetic analysis. 
Homozygous FH were not included in this study. CVD is defined as: coronary 
(myocardial infarction, coronary revascularization procedure, sudden death); cerebral 
(stroke with >24h neurological deficit without evidence of bleeding in brain imaging 
tests); peripheral vascular disease (intermittent claudication with ankle arm index <0.9, 
or arterial revascularization of lower limbs); or, symptomatic or asymptomatic 
abdominal aortic aneurysm. Arterial hypertension was defined as systolic blood 
pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or self-reported use of 
antihypertensive medication. Diabetes was defined as fasting plasma glucose ≥126 
mg/dl, HbA1c ≥6.5% or self-reported treatment with antidiabetic medication. Current 
smoking was defined as smoking in the present or having smoked in the last year. 
Former smoker was defined as a subject having smoked at least 50 cigarettes in his 
lifetime, but not having smoked in the last year. Severe high LDL cholesterol was 
considered when >250 mg/dl in absence on lipid-lowering drugs [12]. 
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Lipid-lowering treatment was classified into three categories according to the type 
of drug and the daily dose: low intensity treatment (ezetimibe 5-10 mg, simvastatin 5-10 
mg, lovastatin 20 mg, pravastatin 10-20 mg, fluvastatin 20-40 mg or pitavastatin 1 mg), 
moderate intensity treatment (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvastatin 
20-40 mg, fluvastatin 80 mg, lovastatin 40 mg, pravastatin 40 mg or pitavastatin 2-4 
mg) and high intensity treatment (rosuvastatin 20-40 mg, atorvastatin 40-80 mg, or any 
daily statin doses plus ezetimibe) [19]. Only extended lipid-lowering (>6 months) at 
entry was considered.  
We conducted this study in accordance with the Declaration of Helsinki for the 
protection of the rights and welfare of people participating in biomedical research.  
 
2.2 Statistical analysis 
Prevalence and HeFH description used the information at the time of data 
collection.  Cases were participants who had suffered a first CVD event and controls 
were the remainder participants. Lipid-lowering treatment use defined the exposure 
variable. A participant was deemed exposed to lipid-lowering treatment if the recorded 
treatment start age predated the first CVD event in cases, and in all cases of treatment in 
controls. Duration of exposure was used for a dose-effect analysis. Years of lipid-
lowering therapy were calculated by subtracting age of treatment to age of event among 
cases, and age of treatment to age at the time of data collection among controls. This 
variable was categorized in non-exposed, and tertiles of duration among those exposed 
(resulting in cutoff values at 5 and 12 years of treatment). Case-control age, for 
adjustment, was that of the first CVD event for cases and that at the time of data 
collection for controls. Other clinical variables used as potential determinants of CVD 
were values present at the time of data collection for both cases and controls. 
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Odds ratios (OR) were estimated using several logistic regression models with 
progressive adjustment: Model 1 was unadjusted, model 2 was adjusted for gender and 
age, model 3 was further adjusted for hypertension, diabetes, tobacco, HDL cholesterol 
(mg/dl), LDL cholesterol (mg/dl), and body mass index (BMI) (kg/m2), and model 4 
additionally for lipoprotein (a) [Lp(a) mg/dl]. 
A second logistic regression analysis with the same progressive adjustments was 
performed restricted to those exposed to high intensity treatment (as defined above) to 
study factors that influence CVD among those under such treatment.  
 
3. Results 
3.1 Study population 
A total 1958 HeFH patients, 1016 women and 942 men, with a mean age of 49.3 
years fulfilled inclusion criteria.  Probable (6-8 DLCN points) and definite HeFH (>8 
DLCN points) was diagnosed in 354 (18.12 %) and 1604 (81.98%) subjects, 
respectively. A positive genetic diagnosis was present in 1273 (65.0%) subjects. At 
inclusion in the registry, 295 patients (15.1%) had suffered CVD. Prevalence of CVD 
among HeFH increased with age and male gender (Fig. 1). Subjects with CVD were 
older, more frequently men, had higher BMI, tobacco consumption, and had more 
frequently hypertension and diabetes than those HeFH without CVD. In addition, HeFH 
patients with CVD had lower HDL cholesterol and higher LDL cholesterol, 
triglycerides and Lp(a) concentrations without lipid-lowering treatment (Table 1).  
 
3.2 Effect of exposure to lipid-lowering treatment on CVD 
Among HeFH patients with CVD, the first event occurred before the onset lipid-
lowering treatment in 164 (55.6%) of the subjects. This percentage was slightly higher 
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for men (56.9%) than for women (52.7%) and had a tendency to decrease with age in 
both genders (Fig.2).  
The mean exposure time to lipid-lowering treatment was 9.7 years, being lower in 
subjects with CVD, although without reaching statistical significance (Table 2). 
To better establish the impact of lipid-lowering treatment on CVD we calculated the 
risk of presenting a first CVD event according to previous exposure to lipid-lowering 
treatment and its duration. Treatment exposure was associated with more than ten times, 
gender and age adjusted, lower odds of CVD than treatment naïve patients (OR 0.085, 
95% CI 0.063 to 0.114, p<0.001) (Supplemental Figure).  This CVD protection was also 
analyzed as the lipid-lowering treatment exposure increased. According to tertiles of 
years of exposure to statins, with respect to those not exposed to statins, the OR for 
those subjects with exposure <5 years, between 5 and 12 years and >12 years, was 
0.095 (95% CI 0.065 to 0.139), 0.086 (95% CI 0.058 to 0.128) and 0.071 (95% CI 0.047 
to 0.108), respectively, with significant differences versus non-exposed (p<0.001 in all 
cases) (Table 3). There was a trend for a greater protection among longer exposures but 
due to the small number of events among those exposed, the differences did not reach 
statistical significance. These ORs remained similar after further adjustment for sex, 
age, BMI, hypertension, diabetes, tobacco, HDL cholesterol and LDL cholesterol levels 
without treatment.  Adjustment for Lp(a) concentration did not modify ORs in the 
regression (Table 3). 
 
3.3 Risk factors for CVD in subjects with lipid-lowering treatment 
 A first CVD event occurred in 131 out of 1615 (8.1%) HeFH subjects already in 
extended lipid-lowering (>6 months) treatment. Among them, 115 (84.6%) were on 
high intensity therapy, including 75 (65.2%) combining ezetimibe, and 93 (71.0%) had 
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a positive genetic diagnosis. Clinical characteristics of these groups are shown in Table 
2. There were more men and they were older, with higher BMI, more prevalence of 
hypertension and diabetes, more often confirmed genetically, and higher LDL 
cholesterol levels without lipid-lowering treatment among HeFH with CVD event than 
among HeFH without it. There were not differences in the presence of xanthomas, 
tobacco consumption, Lp(a) concentration and years of exposure to lipid-lowering 
treatment. 
Two regression analysis calculating OR for CVD after lipid-lowering treatment are 
shown (Supplemental Table). The first analysis included all exposed HeFH subjects to 
treatment and in the second only those subjects treated with high intensity therapy. 
Independent risk factors were male gender, BMI, LDL cholesterol without treatment, 
history of hypertension or diabetes, less than 5 years of lipid-lowering treatment, onset 
of lipid-lowering at age >30 years, and a positive genetic test for FH. The intensity of 
association of these factors with CVD was similar in subjects with high intensity 
treatment to that in the whole group. 
Then, restricted to those subjects treated with high intensity therapy. In this group 
the mean dose of atorvastatin or rosuvastatin was 41.8±0.61 or 24.8±0.44 mg/day, 
respectively, and 738 (64.9%) subjects were also taking ezetimibe. We calculated the 
proportion of subjects who developed CVD according to the count of independent risk 
factors found in the previous logistic regression analysis.  CVD prevalence increases as 
the number of risk factors increases (Figure 3). Among our HeFH population with statin 
treatment previous to CVD, and treated with high intensity therapy, 56.2% showed ≤3 
risk factors, but still 34 (5.3%) had developed CHD in spite of having undergone an 
average of 9.7 years of previous lipid lowering treatment. 
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4. Discussion 
In the present study, we describe the prevalence of CVD in a registry of HeFH 
patients treated in specialized lipid units and the effect on CVD of prolonged treatment 
with lipid-lowering drugs. This is the first work where we can describe the 
characteristics of HeFH that suffered CVD in spite of lipid-lowering treatment, even 
with some of them on high intensity treatment, and provide information to assess the 
potential role of new drugs in the treatment of this disease. 
In our opinion, three important conclusions can be drawn from our work. First, 
current CVD prevalence in HeFH is much lower in the statin era than was reported 
several decades ago; second, CVD in HeFH patients is highly dependent of the moment 
when lipid-lowering is started; and third, new cases of CVD under prolonged statin 
treatment are uncommon and concentrated in subjects with certain risk factors. 
Altogether, our results would indicate that with lipid-lowering treatment is started early 
in life, HeFH is no longer a high-risk CVD condition. 
CVD prevalence estimated from this study is similar to that reported in other 
current registries from specialized lipid centers and, as expected, is highly dependent on 
the mean age of the cohort. The HeFH cohort from The Netherlands with a mean age of 
38.3 years showed a CVD prevalence of 9.2% among 14,283 HeFH [20]; in a cohort 
from Canada with a mean age of 43.9 years it was 12.1% [21]; in our cohort with a 
mean age of 49.3 years it was 15.1%; and in Norway with a mean age of 58 years 
increased to 24% [22]. These prevalences are clearly much lower those reported years 
ago [23] and could probably be related to multiple factors including reduction of 
smoking habit that has been reduced near 50% in males in Spain in the last 20 years 
[24,25]; better medical cardiovascular risk factor control, specially hypertension [26]; 
and changes in the diagnosis of HeFH from clinical diagnosis where the weight of the 
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family and personal history of coronary disease is very strong and favors the selection 
of more serious cases versus the diagnosis based in the genetic diagnosis that eliminates 
these potential biases. In addition, early initiation of statin therapy seems to play major 
role [16].  In fact, in our sample over 50% of HeFH subjects who developed CVD it 
happened before initiating lipid-lowering treatment, while among all the patients that 
initiated treatment while free from CVD, only 8% had a subsequent CVD event. 
We quantified the impact of lipid-lowering drugs, mainly statins, on CVD 
prevention in HeFH. In absence of randomized clinical trials with clinical events as 
main end-point, observational studies contribute to analyze this effect. Considering that 
the mean reduction of LDL cholesterol in our cohort was approximately 50%, which 
corresponds approximately to 135 mg/dl (3.5 mmol/L), the Cholesterol Treatment 
Trialists’ (CTT) Collaboration [27] and epidemiological prospective studies [28] would 
predict a reduction of approximately 59% in CVD incidence in 5 years, because in 
mathematical terms, the decrease in CVD risk should be 0.78 to the power of the LDL 
cholesterol reduction in mmol/L [29]. Applying the formula relative risk ≈ OR / [1 – 
absolute risk + (absolute risk · OR)], an OR= 0.10, that we find in our study, proyecting 
from, as an example, and an untreated absolute risk of 50% in HeFH, our OR would 
correspond to a relative risk of 19%, which corresponds to an 81% reduction. The 
impressing magnitude of the protection found in our work may be explained because the 
mean treatment duration in our study is almost 10 years. The estimation obtained in the 
present study overcomes that figure probably because the mean treatment duration in 
our study was almost 10 years, LDL cholesterol is the major, if not the only risk factors 
in many HeFH patients, and the treatment was started in most cases in primary 
prevention to avoid the development of atherosclerosis which is probably more effective 
than in subjects with advanced disease [29]. This result is in agreement with the large 
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CVD benefit observed of LDL cholesterol lowering effect of certain genetic variation 
that reduced LDL cholesterol early in life [28,30]. Our results emphasize the importance 
of an early in life diagnosis and intense treatment of HeFH [1,31].  
Although CVD is drastically reduced with high intensity lipid-lowering treatment 
in our study, approximately 10% of HeFH patients that started treatment free of CVD 
events still had one event in spite of treatment, some of them even after more than 12 
years of treatment. Probably, this group of patients are good candidates for more potent 
lipid-lowering treatments such inhibition of PCSK9 with monoclonal antibodies. The 
analysis of our cohort would indicate that HeFH subjects with 4 or more risk factors 
including: male gender, statin treatment duration less than 5 years, obesity, diabetes, 
hypertension, LDL cholesterol >250 mg/dl without treatment, presence of a causative 
mutation in candidate genes, or late-in-life initiation of statin treatment would be 
probably the best candidates for such approach. These conditions are well-recognized 
risk factors in general population and HeFH [32]. In contrast, CVD risk for HeFH 
subjects with early-in-life initiation, more than 5 years of treatment, and free from other 
risk factor is reasonably good. 
Limitations. The design of our registry does not reliably allow calculating the 
cumulative LDL cholesterol of the subjects. This calculation has been related to the risk 
of cardiovascular disease [1]. However, the fact that CVD decreases so significantly 
with treatment suggests that cumulative LDL cholesterol above a certain threshold that 
many HeFH get with high-intensity lipid-lowering treatment is even more important 
than the total cumulative LDL cholesterol. During the period of registered treatment 
(approximately 10 years in average) it may not remain constant. We have information 
about the time of treatment onset but covariates are collected at the time of inclusion in 
the registry. However, these patients are usually treated with potent therapies from the 
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very beginning. Although all lipids clinics in the network follow homogeneous 
recommendations for the treatment of HeFH, some differences may be present. In 
addition, HeFH patients in our registry are followed at specialized lipid clinics, and 
perhaps, their phenotype or their management do not fully represent the whole spectrum 
of HeFH in the population. Finally, the retrospective study design implies that only 
HeFH who lived enough time to be registered in our sites are included, and thus most 
severe phenotypes leading to premature death, as well as mortal CVD episodes have not 
been considered, although cardiovascular death has been reported very low in HeFH 
under high intensity treatment [33].  
In conclusion, current prevalence of CVD among treated HeFH in specialized lipid 
clinics for long period of time is one third of that reported before the statins were 
available. Early initiation and prolonged lipid-lowering treatment are associated with 
most of this benefit. However, new cases of CVD appear in spite of high-intensity statin 
but these episodes occur among high risk patients that should be considered for further 
lipid-lowering drugs such as PCSK9 inhibitors.   
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Figure legends 
Figure 1. Prevalence of cardiovascular disease according to age at the moment of entry 
in the registry stratified by gender. 
CVD, cardiovascular disease. 
 
Figure 2. Distribution of a first cardiovascular event in relation to the onset of lipid-
lowering treatment stratified by age and gender. 
CVD, cardiovascular disease. 
 
Figure 3. Prevalence of cardiovascular disease among HeFH in high-intensity lipid-
lowering treatment stratified by the count of cardiovascular risk factors. 
CVD, cardiovascular disease. 
The risk factors considered were those that were statistically significant in Regression 1 
described in Supplemental Table. 
 
Supplemental Figure. Crude proportions of participants with previous lipid-lowering 
treatment exposure on the case (Cardiovascular Disease Present) and control 
(Cardiovascular Disease Absent) groups, and crude ORs for each age and sex stratum. 
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Table 1. Anthropometric, clinical and biochemical characteristic of HeFH subjects at registry inclusion. 
Variables Total (n=1958) Non-CVD (n= 1663) CVD (n= 295) pa 
Age at registry, years 49.3 ± (14.3) 47.8 ± (14.3) 58.0 ± (10.2) <0.001 
Case-control ageb, years 47.7 ± (13.7) 47.8 ± (14.3) 47.6 ± (9.9)  0.267 
Gender (Male) 48.1 (942) 44.4 (738) 69.2 (204) <0.001 
Body mass index, (Kg/m2) 26.2 ± (4.4) 25.9 ± (4.4) 28.1 ± (4.3) <0.001 
Xanthomas, % (n) 32.0 (626) 31.9 (530) 32.5 (96) 0.545 
Tobacco consumption    0.001 
Never smoke, % (n) 53.9 (1056) 56.0 (932) 42.0 (124) 
Ever smoke, % (n) 46.1 (902) 44.0 (731) 58.0 (171) 
Hypertension, % (n) 19.6 (383) 15.5 (258) 42.4 (125) <0.001 
Diabetes, % (n) 6.5 (128) 4.4 (73) 18.6 (55) <0.001 
Lipids without treatment     
Total cholesterol, mg/dl 348 ± (76.2) 345 ± (72.0) 362 ± (95.0) <0.001 
HDL cholesterol, mg/dl 54.8 ± (15.7) 55.8 ± (15.5) 49.2 ± (15.8) <0.001 
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LDL cholesterol, mg/dl 269 ± (74.7) 267 ± (69.9) 285 ± (96.3) <0.001 
Triglycerides, mg/dl 132 ± (118) 128 ± (120)  157 ± (98.2)  <0.001 
Lipoprotein (a), mg/dl (n=1360) 49.4 ± (56.9) 47.8 ± (57.0) 59.0 ± (55.6) 0.004 
Clinical HeFH diagnosis    0.101 
Probable (6-8 DLCN points), % (n) 18.1 (354) 17.4 (290) 21.7 (64) 
Definite (>8 DLCN points), % (n) 81.9 (1604) 82.6 (1373) 78.3 (231) 
Genetic test    <0.001 
Unknown, % (n) 24.4 (478) 22.9 (381) 32.9 (97) 
Negative, % (n) 10.6 (207) 11.3 (188) 6.4 (19) 
                                  Positive, % (n) 65.0 (1273) 65.8 (1094) 60.7 (179) 
 
Values are numbers (%), mean ± (SD), as applicable. CVD denotes cardiovascular disease; HDL, high-density lipoprotein; HeFH, heterozygous 
familial hypercholesterolemia; LDL, low-density lipoprotein; DLCN, Dutch Lipid Clinic Network. 
a p values refer to differences calculated after adjusting gender and case-control age, as appropriate 
b
 Case-control age refers to the age of controls at their inclusion in the registry, and the age of the first CVD event in the group of cases. 
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Table 2. Anthropometric, clinical and biochemical characteristics of HeFH subjects with and without CVD after lipid-lowering treatment. 
Variables No CVD n =1484 CVD n =131 p 
Control-cases age, years 48.3 ± (14.1) 50.0 ± (10.8) 0.022 
Gender (Male), % (n) 45.3% (672) 67.2% (88) <0.001 
Body Mass Index, Kg/m2 25.9 ± (4.3) 28.3 ± (4.5) <0.001 
Xanthomas, % (n) 33.7% (484) 37.3% (47) 0.660 
Tobacco consumption   0.848 
Never smoker, % (n) 55.3% (821) 51.1% (67) 
Ever smoker, % (n) 44.7% (663) 48.9% (64) 
Hypertension, % (n) 15.5% (230) 38.9% (51) <0.001 
Diabetes, % (n) 4.2% (63) 20.6% (27) <0.001 
Pre-treatment LDL-cholesterol, mg/dl 268 ± (69.0) 295 ± (102) <0.001 
Post-treatment LDL-cholesterol, mg/dL 140.1± (49.9) 126.7 ± (49.1) 0.016 
Lp(a), mg/dl (n=1169) 47.7 ± (57.4) 55.8 ± (50.8) 0.152 
Treatment intensity   0.014 
Unknown, % (n) 8.5 (126) 7.6 (10) 
Low intensity, % (n) 1.9% (28) 0.8% (1) 
Moderate intensity, % (n) 20.8% (309) 3.8% (5) 
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Values are numbers (%), mean ± (SD), as applicable. p values refer to differences calculated after adjusting by gender and age, as appropriate. 
CVD denotes cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; LDL, low-density lipoprotein; Lp(a), lipoprotein (a). 
High intensity, % (n) 68.8% (1021) 87.8 (115) 
Time with lipid-lowering treatment, years 9.8 ± (7.4) 9.1 ± (7.2) 0.085 
Probable FH, % (n) 17.0% (253) 16.0% (21) 0.540 
Definite FH, % (n) 83.0% (1231) 84.0% (110) 
Genetic test   0.324 
Positive test genetic, % (n) 67.0% (994) 71.0% (93) 
Negative test genetic, % (n) 11.8% (175) 7.6% (10) 
Unknown, % (n) 21.2% (315) 8.2% (28) 
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Table 3. Odds ratio (OR) for cardiovascular disease according to lipid-lowering treatment in subjects with heterozygous familial 
hypercholesterolemia.        
 OR (CI 95 %) 
 
p Lipid-lowering treatment p 
Exposure 
Yes vs No 
Non-
Exposure  
< 5 years 5.12 years >12 years 
n/N 131/1615 vs 164/343  164/343 48/575 42/499 41/541  
% subjects 
with CHD  
8.1 % vs 47.8 % <0.001 47.8 % 8.3 % 8.4 % 7.6 % <0.001 
Model 1 
N=1958 
0.096 (0.073-0.121) <0.001 REF 0.099 
(0.069-0.143) 
0.100 
(0.069-0.147) 
0.090 
(0.061-0.131) 
<0.001 
Model 2 
N=1958 
0.085 (0.063-0.114) <0.001 REF 0.095 
(0.065-0.139) 
0.086 
(0.058-0.128) 
0.071 
(0.047-0.108) 
<0.001 
Model 3 
N=1958  
0.092 (0.067-0.126) <0.001 REF 0.115 
(0.077-0.171) 
0.089 
(0.058-0.136) 
0.070 
(0.045-0.110) 
<0.001 
Model 4 
n=1360        
0.082 (0.054-0.123) <0.001 REF 0.096 
(0.058-0.160) 
0.076 
(0.045-0.130) 
0.070 
(0.040-0.121) 
<0.001 
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n/N denotes number with CVD/ number in the exposure group. 
Model 1: Univariate analysis  
Model 2: After adjustment for gender and age. 
Model 3: After adjustment for gender, age, hypertension, diabetes, tobacco consumption, HDL cholesterol (mg/dl), LDL cholesterol (mg/dl), and 
body mass index (Kg/m2). 
Model 4: After adjustment for gender, age, hypertension, diabetes, tobacco consumption, HDL cholesterol (mg/dl), LDL cholesterol (mg/dl), 
body mass index (Kg/m2), and lipoprotein (a) (mg/dl).  
F-test p are those for the lipid-lowering treatment variables. 
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Figure 1 
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Figure 2. 
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Figure 3. 
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Highlights 
 
1. Statins have changed the natural history of CVD in HeFH 
2.  We report the current CVD prevalence in HeFH after an average of 9.7 years of 
statins 
3. 10% of HeFH suffered a CVD event after more than 12 years of statin treatment 
4. HeFH at high risk with high-intensity statins are those with >3 risk factors 
5. This study identifies HeFH patients susceptible for more intensive treatment 
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